Clinical Trials Logo

Exercise Performance clinical trials

View clinical trials related to Exercise Performance.

Filter by:

NCT ID: NCT06374641 Recruiting - Cognitive Function Clinical Trials

The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function

MCh1
Start date: March 26, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the effects of taking a new supplement for 16 days on cognitive function and exercise performance, compared to a placebo (a supplement that looks and tastes the same, but doesn't have the same ingredients) in 40 healthy individuals - 20 young individuals (aged 18-30) and 20 older individuals (aged 50-65). The main questions it aims to answer are: - If taking the supplement for 16 days improves exercise performance, or the speed with which the body responds to the commencement of exercise. - If taking the supplement improves cognitive function. Participants will visit the lab on 5 separate occasions to: - complete some cognitive tests - complete exercise performance tests - provide blood samples All exercise tests will be on an exercise bike. After 28 (or 46 for pre-menopausal females) days to make sure the supplement has left the body fully, participants will consume the opposite supplement and repeat the tests.

NCT ID: NCT06349018 Recruiting - Clinical trials for Exercise Performance

Effects of Isotonic Beetroot Supplementation on Sprint Interval Exercise Performance

Start date: February 20, 2024
Phase: N/A
Study type: Interventional

This study aims to examine the effects of dietary nitrate supplementation via beetroot juice on sprint interval cycling exercise performance. Twenty-four participants (male or female) will undertake a randomized, crossover trial where they consume either (i) an isotonic beetroot juice drink containing nitrate (12.9 mmol) for 5 days or (ii) an isotonic sports drink (no nitrate) for 5 days. On Day 5 of each trial, participants will come to the laboratory and 2 hours after consuming their allocated drink will complete a 6 bouts of sprint interval exercise. Power output during cycling will be measured as the primary outcome measure. Salivary and plasma measures of nitrate and nitrite will be taken over the course of the morning on Day 5. After a 5-day washout period participants will crossover and begin their second trial.

NCT ID: NCT06308731 Recruiting - Cognition Clinical Trials

Exercise-Induced Rates of Fat Oxidation With and Without Ingestion of a Caffeine-Based Energy Drink

EDX
Start date: January 19, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate acute changes in rates of fat oxidation during exercise with and without the ingestion of a caffeine-based energy drink.

NCT ID: NCT06217549 Completed - Clinical trials for Exercise Performance

Effect of Ozone Therapy on Aerobic Exercise Performance

Start date: August 12, 2019
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the effect of the ozone therapy applied using the major autohemotherapy method on exercise performance in male healthy individuals. The main question's aims to answer are: - Is ozone therapy applied with the major autohemotherapy method increase the performance? - Is ozone therapy applied with the major autohemotherapy method improve the recovery after exercise? - Participants are asked to continue the same exercise program throughout the study. They were given 10 sessions of ozone therapy over 6 weeks. Researchers compared the before and after treatment performance and recovery data.

NCT ID: NCT06165523 Completed - Clinical trials for Exercise Performance

Kefir Versus Milk on Time-Trial Performance in Masters Athletes

KVM
Start date: March 7, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of added probiotic cultures to a carbohydrate + protein recovery beverage compared to a similar recovery beverage without probiotic cultures, in its ability to impact endurance performance, perceived ratings of gastrointestinal symptoms and markers of inflammation and intestinal damage.

NCT ID: NCT06105671 Not yet recruiting - Clinical trials for Exercise Performance

U-LABA/ICS Effects on Exercise Performance, Formoterol

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

NCT ID: NCT06092723 Completed - Clinical trials for Exercise Performance

Effects of Probiotics Improves the Endurance and Explosiveness Exercise Performance on Healthy Human.

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

This study may discover that supplementing with probiotics LY-66, PL-02 can promote exercise endurance, explosive power and reduce muscle inflammation index in healthy people.

NCT ID: NCT06077019 Recruiting - Clinical trials for Exercise Performance

Role of Lung Function for Exercise Capacity in Well-trained Individuals

Start date: October 5, 2023
Phase: N/A
Study type: Interventional

The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate

NCT ID: NCT06067100 Recruiting - Clinical trials for Exercise Performance

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Start date: October 5, 2023
Phase: N/A
Study type: Interventional

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate

NCT ID: NCT06066606 Recruiting - Clinical trials for Exercise Performance

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Start date: October 5, 2023
Phase: N/A
Study type: Interventional

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate